SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.52+0.4%Nov 28 12:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Clarksterh who wrote (16862)5/19/2005 2:58:03 PM
From: Biomaven  Read Replies (2) of 52153
 
Clark,

This goes to the whole issue of surrogate endpoints for approval in cancer. There's been a lot of discussion at the FDA ODAC meetings - I'd search on the FDA site for details. There's also been some other reasearch - a quick google search turned up this 2003 ASCO cite for example:

The relationship between surrogate markers and survival in women receiving first-line chemotherapy for advanced breast cancer

asco.org

I think the short answer is that TTP generally does correlate with survival, and likely RR does to. But it may well vary by cancer type.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News